Opinion EDITORIAL Philip O. Ozuah, MD, PhD Eleven months into the global coronavirus disease 2019 In the US, most patients with SCD have African ancestry, (COVID-19) pandemic that has disproportionately sickened and which can be traced in turn to the United States’ original in- killed people of color and the poor in the US, in this issue of volvement in slavery. Limiting this population’s access to a JAMA Pediatrics DeMartino et al have delivered what amounts cure for a chronic disease that denies them a normal life from to an early warning about childhood on would be a cruel extension of the countless in- what may well be the next justices inflicted on their forebears. It would also be Related article page 617 manifestation of the sys- consistent with the woeful history of SCD treatment in the US. temic disparities that continue to plague health care in the US. While the disease was first described by James B. Herrick in In their assessment of the budget impact and affordability of 1910, the first drug to treat it, hydroxyurea, was not approved a gene therapy for severe sickle cell disease on the 10 state Med- in the US until 1998.
JAMA Pediatrics – American Medical Association
Published: Jun 22, 2021